Newsroom

April 2020

• Press release Apr 22, 2020

  Novartis Kymriah® receives FDA Regenerative Medicine Advanced Therapy designation in follicular lymphoma

  If approved, relapsed or refractory (r/r) follicular lymphoma would become the third B-cell malignancy indication for Kymriah, joining approvals in children and young adults with r/r ALL, and adults…
• Press release Apr 21, 2020

  AveXis Community Statement on the Coronavirus Disease (COVID-19)

  Dear SMA Community, Like many organizations across the United States and around the world, AveXis is closely monitoring the coronavirus disease (COVID-19) and its impact on patients, the SMA…
• Press release Apr 21, 2020

  Novartis announces new Mayzent® (siponimod) data show sustained effect in delaying disability for up to five years in patients with secondary progressive multiple sclerosis (SPMS)

  New long-term data from EXPAND show patients with SPMS continuously treated with Mayzent® (siponimod) experienced lower risk of disability progression and cognitive decline than patients who delayed…
• Featured News Apr 20, 2020

  World Malaria Day 2020

  This year, World Malaria Day is happening as countries around the world are fighting the COVID-19 pandemic.
• 
  Story Apr 20, 2020 People and Culture

  Going the extra mile to keep clinical trials on track during the COVID-19 pandemic

  A Novartis team couriers an experimental treatment across Europe to a patient as transit grinds to a halt.

• Press release Apr 20, 2020

  Novartis to sponsor large clinical trial of hydroxychloroquine in hospitalized COVID-19 patients

  Novartis has reached an agreement with the US Food and Drug Administration (FDA) to proceed with a Phase III clinical trial of hydroxychloroquine in hospitalized patients with COVID-19 disease Trial…
• Press release Apr 20, 2020

  Novartis acquires Amblyotech, pursuing novel digital therapy for children and adult patients with “lazy eye”

  Technology has potential to reimagine treatment for amblyopia (“lazy eye”), a leading cause of vision loss in children and young adults1Acquisition expands the Novartis refractive disorder pipeline…
• Statement Apr 17, 2020

  Novartis joins the Accelerating COVID-19 Therapeutic Interventions and Vaccines (ACTIV) initiative

• Press release Apr 16, 2020

  Novartis announces data in Neurology reinforcing the real-world and long-term effectiveness and safety of Aimovig® as a preventive treatment across the full spectrum of migraine

  Real-world evidence supports benefits seen in Aimovig clinical trials  Open-label data highlight long-term efficacy and safety profile of Aimovig in episodic and chronic migraine Post-hoc…
• Featured News Apr 15, 2020

  Novartis ranks #4 in PatientView’s 2019 corporate reputation survey of patient organizations

  The Corporate Reputation of Pharma 2019 global report reflects the findings of a survey conducted by PatientView with patient organizations worldwide.

• 
  Story Apr 09, 2020 Discovery

  COVID-19: Answering your top questions

  Novartis CEO Vas Narasimhan answers questions about COVID-19.

• Featured News Apr 08, 2020

  Novartis completes safety review and initiates update to the Beovu® prescribing information worldwide